BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 7935683)

  • 1. Accumulation of nuclear p53 and tumor progression in bladder cancer.
    Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
    N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
    Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
    J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S; Karlsson MG
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
    J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.